ANXA1 and hyperlipidemia: Since over-expression of 11βHSD1 leads to increased adiposity, elevated leptin levels, insulin resistance and hyperlipidemia [26], while a selective 11βHSD1 inhibitor prevents adipogenesis [31], alteration of this pathway by ANXA1 represents an additional potential mechanism to explain the increased adiposity of KO-HFD mice.